A new NRF2 activator for the treatment of human metabolic dysfunction-associated fatty liver disease

MLA

Adel Hammoutene, et al. “A New NRF2 Activator for the Treatment of Human Metabolic Dysfunction-Associated Fatty Liver Disease.” JHEP Reports, vol. 5, no. 10, Oct. 2023. EBSCOhost, https://doi.org/10.1016/j.jhepr.2023.100845.

APA

Adel Hammoutene, Samira Laouirem, Miguel Albuquerque, Nathalie Colnot, Angélique Brzustowski, Dominique Valla, Nicolas Provost, Philippe Delerive, & Valérie Paradis. (2023). A new NRF2 activator for the treatment of human metabolic dysfunction-associated fatty liver disease. JHEP Reports, 5(10). https://doi.org/10.1016/j.jhepr.2023.100845

Chicago

Adel Hammoutene, Samira Laouirem, Miguel Albuquerque, Nathalie Colnot, Angélique Brzustowski, Dominique Valla, Nicolas Provost, Philippe Delerive, and Valérie Paradis. 2023. “A New NRF2 Activator for the Treatment of Human Metabolic Dysfunction-Associated Fatty Liver Disease.” JHEP Reports 5 (10). doi:10.1016/j.jhepr.2023.100845.